To mark Rare Disease Day 2012, Darren Smyth's latest IPKat post has a topical theme.
Darren highlights the pharmaceutical industry's reluctance to develop treatments for rare diseases where there is little prospect of financial gain, and wonders whether the patent system itself could provide incentives in these cases.